Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900809 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00900809 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 7 participants.
The verdict
NCT00900809, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
NK cells from patients with malignant diseases are often functionally impaired. Their function cannot be fully restored through ex vivo expansion and cytokine activation. In addition, the in vivo administration of cytokines not only expands NK cells but expands polyclonal T cells with no tumor specificity and no known effects. The utilization of Neukoplast™, as a form of adoptive immunotherapy, offers several advantages. Neukoplast™ represents a uniform cell population with a well-characterized immunophenotype, confirmed strong anti-tumor activity and are easy to grow and expand in culture, so that they can be made available in large numbers for therapeutic delivery.
Interventions
- BIOLOGICAL Neukoplast™ (NK-92)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-05-12 |
| Est. Completion | 2015-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900809
The ClinicalTrials.gov registry entry for NCT00900809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neukoplast™ (NK-92) is the first listed.
NCT00900809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900809 about?
NCT00900809 is a clinical study titled "QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia". NK cells from patients with malignant diseases are often functionally impaired. Their function cannot be fully restored through ex vivo expansion and cytokine activation. In addition, the in vivo administration of cytokines not only expands NK cells but expands polyclonal T cells with no tumor speci...
What is the current status of trial NCT00900809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2014-05-12. Estimated completion is 2015-06-02.
What interventions are being tested in trial NCT00900809?
The interventions under investigation include: Neukoplast™ (NK-92) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00900809?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.